Evaluation of Serum Beta-2-Microglobulin Levels in Relation to Metabolic Parameters in CKD Patients

Background: Beta-2-microglobulin (B2M) is a middle molecular weight uremic toxin that accumulates in blood in individuals with advanced stages of chronic kidney disease (CKD). The aim of the study was to evaluate the associations between serum B2M levels and some selected metabolic factors in CKD patients.

Methods: A cross-sectional study was conducted involving 165 patients with CKD across stages G1-G5. Blood samples were collected to assess serum levels of B2M and other metabolic factors, including serum creatinine, albumin-to-creatinine ratio (ACR), serum uric acid, serum albumin, serum calcium, serum phosphate, lipid levels, serum intact parathyroid hormone (iPTH), and high-sensitivity C-reactive protein (hsCRP).

Results: There were differences in serum B2M levels across CKD stages but the differences weren’t linear. Metabolic factors such as serum creatinine, ACR, CRP, serum calcium, serum phosphate, serum uric acid, serum albumin, triglycerides, and iPTH demonstrated significant differences across CKD stages. Serum albumin and serum cholesterol showed negative correlation in stages G4 and G5 with B2M, while iPTH levels showed positive correlations from G2 to G5.

Conclusion: Beta-2-microglobulin levels showed varying degrees of correlation with some metabolic factors, but there was no consistent, stage-by-stage progression or regression pattern with the majority of them.

Cite this article as: Siddiqui NA, Hossain S, Alam A, et al. Evaluation of serum beta-2-microglobulin levels in relation to metabolic parameters in CKD patients. Turk J Nephrol. 2025;34(2):94-98.